[1]Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin, 2018, 68(6): 394-424. [2]Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024 [J]. CA Cancer J Clin. 2024, 74(1):12-49. [3]Torre L A, Bray F, Siegel R L, et al. Global cancer statistics, 2012 [J]. CA Cancer J Clin, 2015, 65(2): 87-108. [4]Sung H, Ferlay J, Siegel R L, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries [J]. CA Cancer J Clin, 2021, 71(3): 209-49. [5]Loibl S, Poortmans P, Morrow M, et al. Breast cancer [J]. Lancet. 2021, 397(10286):1750-1769. [6]Xiong X, Zheng LW, Ding Y, et al. Breast cancer: pathogenesis and treatments[J]. Signal Transduct Target Ther. 2025, 10(1):49. [7]Chen W, Yang J, Fang H, et al. Relevance Function of Linc-ROR in the Pathogenesis of Cancer [J]. Front Cell Dev Biol. 2020, 8:696. [8]Peña-Flores JA, Enríquez-Espinoza D, Muela-Campos D, et al. Functional Relevance of the Long Intergenic Non-Coding RNA Regulator of Reprogramming (Linc-ROR) in Cancer Proliferation, Metastasis, and Drug Resistance [J]. Noncoding RNA. 2023, 9(1):12. [9]Mi Y, Li Y, He Z, et al. Upregulation of Linc-ROR Promotes the Proliferation, Migration, and Invasion of Gastric Cancer Cells Through miR-212-3p/FGF7 Axis [J]. Cancer Manag Res. 2021, 13:899-912. [10]Tan YT, Lin JF, Li T, et al. LncRNA-mediated posttranslational modifications and reprogramming of energy metabolism in cancer. Cancer Commun (Lond) [J]. 2021, 41(2):109-120. [11]Bhan A, Soleimani M, Mandal SS. Long Noncoding RNA and Cancer: A New Paradigm [J]. Cancer Res. 2017, 77(15):3965-3981. [12]Smolarz B, Zadrożna-Nowak A, Romanowicz H. The Role of lncRNA in the Development of Tumors, including Breast Cancer [J]. Int J Mol Sci. 2021, 22(16):8427. [13]Ma Y, Zhang P, Wang F, et al. The relationship between early embryo development and tumourigenesis [J]. J Cell Mol Med, 2010, 14(12): 2697-701.[14]Loewer S, Cabili M N, Guttman M, et al. Large intergenic non-coding RNA-RoR modulates reprogramming of human induced pluripotent stem cells [J]. Nat Genet, 2010, 42(12): 1113-7. [15]Wang Y, Xu Z, Jiang J, et al. Endogenous miRNA sponge lincRNA-RoR regulates Oct4, Nanog, and Sox2 in human embryonic stem cell self-renewal [J]. Dev Cell, 2013, 25(1): 69-80. [16]Hou P, Zhao Y, Li Z, et al. LincRNA-ROR induces epithelial-to-mesenchymal transition and contributes to breast cancer tumorigenesis and metastasis [J]. Cell Death Dis, 2014, 5(6): e1287. [17]Chen W, Wang H, Liu Y, et al. Linc-RoR promotes proliferation, migration, and invasion via the Hippo/YAP pathway in pancreatic cancer cells [J]. J Cell Biochem, 2020, 121(1): 632-41. [18]Li C, Zhao Z, Zhou Z, et al. Linc-ROR confers gemcitabine resistance to pancreatic cancer cells via inducing autophagy and modulating the miR-124/PTBP1/PKM2 axis [J]. Cancer Chemother Pharmacol, 2016, 78(6): 1199-207. [19]Chen Y M, Liu Y, Wei H Y, et al. Linc-ROR induces epithelial-mesenchymal transition and contributes to drug resistance and invasion of breast cancer cells [J]. Tumour Biol, 2016, 37(8): 10861-70. [20]Li X, Sun D, Zhao T, et al. Long non-coding RNA ROR confers arsenic trioxide resistance to HepG2 cells by inhibiting p53 expression [J]. Eur J Pharmacol, 2020, 872: 172982. [21]Mohebi M, Sattari A, Ghafouri-Fard S,et al. Expression profiling revealed up-regulation of three lncRNAs in breast cancer samples [J]. Exp Mol Pathol. 2020, 117:104544. [22]Zhao T, Wu L, Li X, et al. Large intergenic non-coding RNA-ROR as a potential biomarker for the diagnosis and dynamic monitoring of breast cancer [J]. Cancer Biomark, 2017, 20(2): 165-73. [23]Ma J, Yang Y, Huo D, et al. LincRNA-RoR/miR-145 promote invasion and metastasis in triple-negative breast cancer via targeting MUC1 [J]. Biochem Biophys Res Commun, 2018, 500(3): 614-20. [24]Luo C, Cao J, Peng R, et al. Functional Variants in Linc-ROR are Associated with mRNA Expression of Linc-ROR and Breast Cancer Susceptibility [J]. Sci Rep, 2018, 8(1): 4680. [25]Wen X, Wu Y, Lou Y, et al. The roles of Linc-ROR in the regulation of cancer stem cells [J]. Transl Oncol. 2023, 28:101602. [26]Zhou Q, Guo J, Huang W, et al. Linc-ROR promotes the progression of breast cancer and decreases the sensitivity to rapamycin through miR-194-3p targeting MECP2 [J]. Mol Oncol, 2020, 14(9): 2231-50. [27]Eades G, Wolfson B, Zhang Y, et al. lincRNA-RoR and miR-145 regulate invasion in triple-negative breast cancer via targeting ARF6 [J]. Mol Cancer Res, 2015, 13(2): 330-8. [28]Chen Y M, Liu Y, Wei H Y, et al. Large intergenic non-coding RNA-ROR reverses gemcitabine-induced autophagy and apoptosis in breast cancer cells [J]. Oncotarget, 2016, 7(37): 59604-17. [29]Peng W X, Huang J G, Yang L, et al. Linc-RoR promotes MAPK/ERK signaling and confers estrogen-independent growth of breast cancer [J]. Mol Cancer, 2017, 16(1): 161. [30]Zhang H Y, Liang F, Zhang J W, et al. Effects of long noncoding RNA-ROR on tamoxifen resistance of breast cancer cells by regulating microRNA-205 [J]. Cancer Chemother Pharmacol, 2017, 79(2): 327-37. [31]Zhao T, Wu L, Li X, et al. Large intergenic non-coding RNA-ROR as a potential biomarker for the diagnosis and dynamic monitoring of breast cancer [J]. Cancer Biomark, 2017, 20(2): 165-73. [32]Hou L, Tu J, Cheng F, et al. Long noncoding RNA ROR promotes breast cancer by regulating the TGF-β pathway [J]. Cancer Cell Int, 2018, 18: 142. [33]He Y, Liu H, Chen Q, et al. Relationships between SNPs and prognosis of breast cancer and pathogenic mechanism [J]. Mol Genet Genomic Med, 2019, 7(9): e871. [34]Hou L, Tu J, Cheng F, et al. Long noncoding RNA ROR promotes breast cancer by regulating the TGF-β pathway [J]. Cancer Cell Int. 2018, 18:142.